Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

TVGN

Tevogen Bio Holdings Inc.

May 01 • 04:00PM ET

0.9700

Dollar change -0.0300
Percentage change -3.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.04	Insider Own	90.98%	Shs Outstand	14.94M	Perf Week	-35.33%
Market Cap	159.67M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	14.85M	Perf Month	-67.12%
Income	-0.07M	PEG	-	EPS next Q	-	Inst Own	1.06%	Short Float	0.49%	Perf Quarter	-81.59%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	0.47%	Short Ratio	0.13	Perf Half Y	-91.13%
Book/sh	-0.05	P/B	-	EPS next Y	-	ROA	-0.04%	Short Interest	0.07M	Perf Year	-90.42%
Cash/sh	0.00	P/C	15967.17	EPS next 5Y	-	ROE	-0.04%	52W Range	0.80 - 21.09	Perf YTD	-91.28%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-95.40%	Beta	0.48
Dividend TTM	-	Quick Ratio	0.12	Sales past 5Y	0.00%	Gross Margin	-	52W Low	20.80%	ATR (14)	0.44
Dividend Ex-Date	-	Current Ratio	0.12	EPS Y/Y TTM	-144.78%	Oper. Margin	0.00%	RSI (14)	22.08	Volatility	33.14% 20.94%
Employees	17	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-201.83%	Payout	-	Rel Volume	0.32	Prev Close	1.00
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	556.21K	Price	0.97
SMA20	-52.68%	SMA50	-78.29%	SMA200	-88.98%	Trades		Volume	180,380	Change	-3.00%

Today 08:05AM	Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives (GlobeNewswire)
Apr-26-24 09:23AM	Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments (GlobeNewswire) +17.65%
Apr-11-24 08:05AM	Tevogen Bio's Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers (GlobeNewswire)
Apr-03-24 08:05AM	Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development (GlobeNewswire) -11.19%
Mar-28-24 08:05AM	Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price (GlobeNewswire) +8.05%
09:20AM	Loading…
Mar-27-24 09:20AM	Tevogen Bio Announces Series A-1 Preferred Stock Investment (GlobeNewswire) -10.65%
Mar-20-24 07:00AM	Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant (Business Wire)
Mar-05-24 08:00AM	Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita (Business Wire)
Feb-27-24 04:39PM	Mittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI (Business Wire)
Feb-21-24 07:00AM	Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment (Business Wire)
Feb-17-24 12:17AM	Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market (Business Wire)
Feb-15-24 09:25AM	Tevogen Bio Announces $8 Million Equity Investment (Business Wire) +121.73%
Feb-14-24 03:55PM	Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGN (GlobeNewswire)
Feb-01-24 08:15AM	Semper Paratus Acquisition Corporation's Shareholders Approve Business Combination with Tevogen Bio (GlobeNewswire) -8.73%
Jan-24-24 04:05PM	Semper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on Nasdaq (GlobeNewswire)
08:55AM	Loading…
Jan-05-24 08:55AM	Tevogen Bio Inc. and Semper Paratus Acquisition Corporation Announce Effectiveness of Registration Statement for Business Combination (GlobeNewswire)
Sep-29-23 08:50AM	Semper Paratus Acquisition Corporation Regains Compliance with Certain Nasdaq Listing Requirement (GlobeNewswire)
Sep-14-23 05:30PM	Semper Paratus Acquisition Corporation Files Registration Statement on Form S-4 in Connection with Proposed Business Combination with Tevogen Bio Inc (GlobeNewswire)
Jun-29-23 08:05AM	Tevogen Bio to Become Publicly Listed on NYSE via Business Combination with Semper Paratus Acquisition Corporation (GlobeNewswire)

Tevogen Bio Holdings, Inc. is a clinical-stage specialty immunotherapy company. It develops off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company was founded on February 14, 2024 and is headquartered in Warren, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TVGN

Tevogen Bio Holdings Inc.

Upgrade your FINVIZ experience